10,500 Shares in Celcuity, Inc. $CELC Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB acquired a new stake in Celcuity, Inc. (NASDAQ:CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 10,500 shares of the company’s stock, valued at approximately $1,099,000.

Several other large investors have also modified their holdings of CELC. EverSource Wealth Advisors LLC grew its position in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after acquiring an additional 319 shares during the last quarter. US Bancorp DE raised its position in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. BNP Paribas Financial Markets raised its position in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the last quarter. Parallel Advisors LLC acquired a new stake in Celcuity during the 1st quarter worth $38,000. Finally, Meeder Asset Management Inc. acquired a new stake in Celcuity during the 4th quarter worth $42,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Stock Performance

Shares of CELC stock opened at $93.24 on Wednesday. The stock has a fifty day moving average price of $94.00 and a 200 day moving average price of $108.08. The stock has a market cap of $4.55 billion, a PE ratio of -21.68 and a beta of 0.21. Celcuity, Inc. has a 1 year low of $44.42 and a 1 year high of $151.02. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Sell-side analysts forecast that Celcuity, Inc. will post -4.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CELC has been the topic of a number of recent research reports. Citizens Jmp restated a “market outperform” rating and issued a $177.00 price objective on shares of Celcuity in a research note on Monday. Guggenheim boosted their price target on Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Monday. Craig Hallum reaffirmed a “buy” rating and set a $178.00 price objective on shares of Celcuity in a research note on Wednesday, July 15th. Stifel Nicolaus lowered their target price on Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, Wall Street Zen lowered Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $154.55.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.